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Definitive Radiotherapy for 
Locally Advanced Non-Small Cell 
Lung Cancer: Current Status and 
Future Perspectives
Hiroshi Doi and Kozo Kuribayashi
Abstract
Lung cancer remains one of the most common cancers, and the mortality rate 
is still high. Radiotherapy plays an important role in radical treatment for locally 
advanced non-small cell lung cancer. Treatment outcomes in lung cancer have 
improved over the last few decades. Several treatment regimens have been shown 
to be effective and safe. Further, modern technological approaches of radiotherapy 
have been developed along with advanced imaging and immunotherapy in order to 
improve outcomes and minimize radiation-induced toxicity. This chapter sum-
marizes the historical results of the key clinical studies that were conducted in the 
past with the focus on various regimens of chemoradiotherapy used. In addition, we 
discuss future perspectives of definitive radiotherapy for locally advanced non-
small cell lung cancer.
Keywords: lung cancer, radiotherapy, chemoradiotherapy, intensity modulated 
radiation therapy, dulvalumab
1. Introduction
The lung cancer remains one of the most common cancers, and 80% of lung 
cancers account for non-small cell lung cancer (NSCLC) [1]. Patients diagnosed 
at a locally advanced stage represent 20 to 30%, and radical surgery is challenging 
for those patients [1]. Definitive chemoradiotherapy is a well-established treat-
ment option for unresectable locally advanced NSCLC [2, 3]. Treatment outcomes 
in such patients have improved over the last few decades. Several treatment 
regimens have been shown to be effective and safe. Moreover, modern radio-
therapy technologies have been developed along with the development of optimal 
chemotherapy and immunotherapy to improve outcomes and minimize radiation-
induced toxicity. This chapter summarizes historical results of key clinical studies 
in the past in terms of various regimens of chemoradiotherapy. In addition, we 
discuss definitive radiotherapy, which is recommended for locally advanced 
NSCLC. Specifically, we address future perspectives of definitive radiotherapy for 
locally advanced NSCLC.
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2.  History of the development of definitive radiotherapy for locally 
advanced NSCLC
Radiotherapy alone was a standard treatment for inoperable lung cancer up 
to the 1980s based on the results of a randomized controlled trial in the 1960s 
[4]. Perez et al. showed the dose–response efficacy up to 60 Gy, which had been 
a standard dose from the combined results of the RTOG 7101 and 73–02 study 
[5]. After the 1990s, definitive radiotherapy, using ≥60Gy in a conventional 
fractionated regimen, combined with chemotherapy, has been used as a standard 
treatment for unresectable locally advanced NSCLC. In the early 1990s, sequential 
cisplatin-based chemotherapy followed by radiotherapy had been proven to 
have a survival benefit over definitive radiotherapy alone and chemotherapy 
alone for unresectable stage III NSCLC [6–9]. Then, from the late 1990s to the 
2000s, several randomized clinical trials revealed that the concurrent approach 
of chemoradiotherapy enhanced survival compared to the sequential approach 
[10–13]. After 2000, the usefulness of several new agents, such as paclitaxel, 
gemcitabine, vinorelbine, and docetaxel, which are called third-generation 
chemotherapy agents, have been studied. They have been usually administered in 
combination with platinum compounds, and demonstrated increased survival in 
patients with metastatic NSCLC [14, 15]. Although there has been no significant 
improvement in survival achieved with chemoradiotherapy using third-generation 
regimens, it has become a standard treatment with a favorable toxicity  
profile [16, 17].
Some clinical studies conducted between 1990s and 2000s showed that 
hyperfractionated, accelerated radiotherapy was superior to the conventional 
fractionated radiotherapy with a feasible toxicity [18–21]. However, the benefit of 
hyperfractionated, accelerated radiotherapy is controversial, with high risk of acute 
esophageal toxicity; and has been less accepted in clinical practice [2, 21, 22]. After 
2000, the utility of consolidation chemotherapy following chemoradiotherapy has 
failed to prove a significant survival benefit [23–25]. A dose escalation of radiother-
apy has been investigated because loco-regional tumor control might be associated 
with better survival; and there is a potential dose–response efficacy in the control 
of NSCLC using this approach [5, 26]. However, RTOG 0617 trial failed to prove 
benefits on overall survival (OS) and progression-free survival (PSF) using the 
escalated doses of 74 Gy compared to the standard dose of 60 Gy in an open-label 
randomized phase 3 study [27]. Volume prescriptions such as D95 using updated 
calculation algorithms in recent clinical trials could reveal a slightly escalated dose 
for the target, in comparison with the point prescription that has been used in 
previous studies. However, the standard regimen of definitive radiotherapy has 
been 60 Gy in 30 fractions.
As shown in Figure 1, the median survival time after treatment has improved 
with the development of chemoratiotherapy. However, the 5-year survival rate 
has been unsatisfactorily, reaching only up to 20%. Recently, immune checkpoint 
inhibitors (ICIs) have been applied in the treatment of advanced malignancies, 
including lung cancer [29]. ICIs block checkpoint proteins that can weaken immune 
responses by T cells to cancer cells. Recent systematic reviews have demonstrated 
the beneficial effects of ICIs on OS and PSF in advanced NSCLC [30]. The PACIFIC 
trial, a randomized, double-blind, placebo-controlled multi-center trial, has tested 
the efficacy of dulvalumab, which is a human monoclonal antibody directed against 
programmed cell death-ligand 1 (PD-L1), in patients with stage III NSCLC as 
sequential treatment following standard concurrent chemoradiotherapy [19–32]. 
Dulvalumab has brought a breakthrough in the treatment of locally advanced 
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NSCLC in decades, and median survival after treatment has not reached with a 
median follow-up of 33.3 months in a recent updated result [28]. The transition of 
standard definitive radiotherapy for locally advanced NSCLN and representative of 
the clinical outcomes of selected prospective clinical trials with time are shown in 
Table 1 and Figure 1.
Figure 1. 
Improvement of survival outcome of locally advanced NSCLN. (A) Median survival and (B) 3-year overall 
survival per selected prospective clinical studies and meta-analyses [4–13, 16, 17, 23, 24, 27, 28]. Each bar 
indicates the mean value of the results. Radiotherapy group included locally advanced NSCLC patients who 
underwent treatment with standard radiation doses such as ≥60Gy in a conventional schedule. Abbreviations: 
Con-CRT, concurrent chemoradiotherapy; Con-CRT-ICI, concurrent chemoradiotherapy with consolidation 
immune checkpoint inhibitor; RT, radiotherapy; Seq-CRT, sequential chemoradiotherapy.
~ 1980s Radiotherapy alone
1990s Sequential chemoradiotherapy
Concurrent chemoradiotherapy (second-generation regimen)
2000s Concurrent chemoradiotherapy (third-generation regimen)
2020~ Concurrent chemoradiotherapy followed by immune checkpoint inhibitor (dulvalumab)
Table 1. 
Transition of standard definitive radiotherapy for locally advanced NSCLN.
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3.  Utility of intensity-modulated radiotherapy, learning from RTOG 
0617 and PACIFIC trials
RTOG 0617 trial failed to demonstrate the benefit of dose-escalation of 74 Gy 
compared with 60 Gy, but also provided significant information for clinical practice, 
as it was the first phase III NSCLC study to allow intensity-modulated radiotherapy 
(IMRT) as a treatment modality for locally advanced NSCLC, and 46% of enrolled 
patients underwent IMRT [27, 33].
The disadvantage of IMRT in terms of dose distribution is increased volume 
of lungs receiving low-dose radiation, called “low-dose bath” because the IMRT 
plan is created using the increased number of beam angles [34]. Low-dose baths 
represented by large volumes of lung V5 (the volume of the lungs receiving 
≥5 Gy) has been reported to increase the risk of acute and late pulmonary toxicity 
[34–36]. IMRT was used to treat larger and unfavorable tumors in RTOG 0617 
[37]. Lung V5 was significantly higher in the IMRT group than in the 3D-CRT 
group. However, IMRT was associated with lower rates of severe pneumonitis 
in the RTOG 0617 prospective clinical trial. In addition, severe pneumonitis 
was predicted by lung V20, but not V5. Thus, V20 has been confirmed as a well-
established risk factor of radiation pneumonitis with high reproducibility [38]. It 
is difficult to clarify the controversial meaning of V5 as a predictor of radiation 
pneumonitis. However, IMRT could improve target coverage and reduce the 
volume of normal lungs irradiated with intermediate doses such as V20 [34]. 
Grade ≥ 2 pneumonitis after chemoradiotherapy was a significant exclusion 
criterion in the PACIFIC trial [31]. The reduction of the risk of radiation pneumo-
nitis by using IMRT might maximize the opportunity of receiving consolidation 
ICI based on the PACIFIC trial, although detailed data on radiotherapy was not 
collected in the PACIFIC trial [28, 31, 32, 37].
Higher doses to heart and esophagitis were associated with poor survival 
[37, 39]. In patients receiving heart V50 < 25% versus ≥25, the 1-year OS rates 
were 70.2% versus 46.8% and the 2-year OS rates were 45.9% versus 26.7% 
(p < 0.0001) [39]. Heart V40, which has been shown to be a prognostic factor for 
survival, can be substantially reduced with IMRT compared to 3D-CRT. In addi-
tion, the use of IMRT was associated with significantly less decline in quality of 
life [40]. These toxicities were potentially associated with poor survival in patients 
treated with escalated radiation doses of 74 Gy [27]. Furthermore, the correlation 
of institution accrual volume with the treatment outcomes is controversial but can 
be associated with other malignancies such as head and neck cancers [39, 41–43]. 
Quality assurance and institutional experience seem important in radical treat-
ment of locally advanced NSCLC.
The benefits of proton therapy have been reported and included a better dose 
distribution to the lung and heart in treatment plan than in photon radiotherapy 
[44]. A randomized control study that compared the utility of proton therapy with 
that of IMRT showed no significant benefit in terms of the occurrence of radia-
tion pneumonitis and local failure [45]. Modern proton techniques might improve 
clinical outcomes, but there is no significant evidence of a superiority of proton 
therapy over IMRT at this moment.
IMRT allows the treatment of challenging cases with dosimetric and clinical 
benefits. Therefore, IMRT is a current standard technique in the definitive radio-
therapy for advanced NSCLC, as the use of IMRT has various advantages over 
3D-CRT, which obviously outweighs the disadvantages.
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4. Tips for using definitive radiotherapy for locally advanced NSCLC
4.1 Involved-field radiotherapy
The European Society for Radiotherapy and Oncology recommends that meta-
static nodes and the applicable margin with no further elective lymph nodes should 
be included in clinical tumor volume (CTV) [46]. Radiotherapy has been prescribed 
to the intersection point of the treatment beams [18]. An initial radiotherapy was 
administered to the anteroposterior parallel–opposed pair of portals and then to a pair 
of oblique fields during the boosted radiotherapy [16]. Traditionally, definitive radio-
therapy for locally advanced NSCLC targets the primary disease and nodal metastases 
as well as the mediastinum and ipsilateral hilum whether or not there is clinical 
involvement of all nodal stations [6, 7, 9–11, 13, 17, 18, 22]. This technique is known as 
elective nodal irradiation (ENI). Potential dose–response has been reported, and an 
increased radiation dose has been believed to improve survival in NSCLC before RTOG 
0617 [5, 26]. Involved field radiotherapy (IFRT) is a radiation treatment technique that 
minimizes the radiation dose to uninvolved areas [47]. For example, Figure 2 indicates 
the difference in planning target volume (PTV) between ENI and IFRT. IFRT allows 
radiation doses to be increased to the primary tumor and involves mediastinal lymph 
nodes. Thus, landmark clinical trials testing dose escalation adopted IFRT [27, 48, 49]. 
Although there are limited data directly comparing IFRT and ENI, the elective nodal 
failure rate after IFRT has been reported to be <10% in most reports [50–56]. Generally, 
EFRT can decrease the risk of severe toxicities, including acute esophagitis and pneu-
monitis, while showing no significant differences in elective nodal failure rate and sur-
vival outcomes in comparison with ENI [54–56]. Importantly, metastatic nodes should 
be defined with the guidance of PET images [46, 57]. Thereafter, CTV is generated by 
adding 5 to 10 mm to the gross tumor volume (GTV) of the primary tumor (typically 
8 mm and 6 mm for adenocarcinoma and squamous carcinoma, respectively) and 
3 mm for GTV of metastatic nodes of <20 mm [46, 58, 59].
Figure 2. 
Differences in radiotherapy target selection in elective nodal irradiation and involved field radiotherapy. 
Squamous cell carcinoma in the upper lobe of the right lung with nodal metastases (cT3N2M0). Red, green, 
and blue indicates gross tumor volume (GTV), planning target volume (PTV) for elective nodal irradiation 
(ENI), and that for involved field radiotherapy (IFRT), respectively. The clinical target volume (CTV) for ENI 
including the upper mediastinum enlarges the size of the PTV.
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4.2 Respiratory management in locally advanced NSCLC
An important challenge for lung cancer radiotherapy treatment is the manage-
ment of physiological movements related to breathing. The lung tumors can move 
during breathing. Usually, to ensure adequate dose delivery to the tumor, an appro-
priate margin is added around the tumor. Four-dimensional computed tomography 
(4DCT) is a technique that allows to quantify the movement of the tumor with the 
use of respiratory reduction equipment such as an abdominal compression device. 
The internal target volume (ITV) is delineated on the 4DCT scan in order to account 
for tumor motion, and an additional margin is added to generate PTV. However, the 
target is large as it covers the entire tumor motion, especially in tumors in the lower 
lobe of the lung [60].
The breath-hold technique has been used to minimize the target volume, which 
must be irradiated with high-dose radiation and can help to reduce risk of radiation 
pneumonitis (Figure 3). In particular, the deep inspiration breath hold (DIBH) 
technique provides an advantage to a free-breathing treatment and could reduce the 
dosimetric parameters of normal organs such as the lung in dose-volume histo-
grams [61]. DIBH gating has been clinically used in thoracic and upper abdominal 
radiotherapy [62]. In addition, it has recently been reported that compliance and 
reproducibility of DIBH was sufficiently high, with a reported compliant rate of 
72% in a prospective clinical study [63]. DIBH has a high potential as a standard 
treatment in definitive radiotherapy for locally advanced NSCLC.
4.3 Image-guided radiotherapy in locally advanced NSCLC
In recent years, advancements in image-guided radiotherapy (IGRT) technology 
have enabled more accurate positioning and precise radiotherapy. IGRT is an essential 
companion to IMRT and allows the treatment to account for daily changes in target 
anatomy, motion, and positioning. Megavoltage (MV) portal imaging had been 
conventionally used to correct the setup errors and limited to verification of bony 
anatomy. In recent years, the X-ray source for imaging has been evolving from MV 
imaging to kilovoltage (kV) imaging, and from two-dimensional to three- dimensional 
Figure 3. 
Breath hold technique can minimize a target volume. Non-small cell lung cancer in the lower lobe of the left 
lung. Red, orange blue, and green indicate gross tumor volume (GTV), accumulated GTV on four-dimensional 
computed tomography (4DCT), planning target volume (PTV) using the breath-hold technique (exhale), 
and PTV, which was generated by accounting tumor motion in 4DCT, respectively. The breath-hold technique 
reduces the target volume.
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imaging. Modern IGRT is performed with either gantry mounted MV or kV cone beam 
computed tomography (CBCT) or room-mounted kV systems for tracking during 
treatment. IGRT allows for easier and improved accuracy leading more frequent posi-
tioning changes with leading to a therapeutic advantage. Kilburn et al. has reported 
that IGRT using daily CBCT improved locoregional tumor control than radiotherapy 
using weekly MV portal images [64].
Three-dimensional images in CBCT are used not only for positioning but also 
for the evaluation of the radiotherapy planning by dose calculation on the CBCT 
images. It has recently been reported that dose distribution and dose volume 
histogram were accurately calculated on CBCT images with a deformable imaging 
registration [65].
Further, acquired images from CBCT can be used for individualized treatment, 
called adaptive radiotherapy (ART). Since there are possibe changes of tumor and 
surround tissues during the treatment courses due to tumor shrinking and ana-
tomical changes, it is necessary to modify the radiotherapy plan with accounting  
the appropriate margin, positioning, and tumor. CBCT provides significant 
three-dimensional information to evaluate if the patient would benefit from a 
re-scanning and re-planning. Indeed, ART can improve locoregional tumor control 
over radiotherapy without ART [66].
Daily IGRT with CBCT and ART has been reported to reduce toxicity and 
probably increase tumor response due to a better tumor localization and reduction 
of an interfraction target miss due to anatomical changes [64, 66, 67]. Further 
studies should be conducted in order to establish the optimal systemic replanning 
technique.
5.  Future perspectives of definitive radiotherapy for locally advanced 
NSCLC
5.1 Failure pattern and potential salvage after definitive radiotherapy
Approximately 40% and 50% of locally advanced NSCLC patients experience 
locoregional and distant failures two years after the definitive chemoradiotherapy 
[27]. Consolidation ICI has been proven to reduce disease progression in both the 
intrathoracic and extrathoracic areas [32, 68]. Time to death or distant metastasis 
was longer, and the frequency of new lesions was lower with the use of durvalumab 
in comparison with placebo [32]. Notably, distant failure occurred in one or two 
lesions (66.6% in durvalumab arm) in a single organ (95.2% in durvalumab arm) 
at first progression in both arms of durvalumab and placebo with a median follow-
up of 25.2 months [68]. Therefore, there seems to be a window of opportunity for 
treating these limited failures as a salvage, which might lead to a longer survival 
[69–71]. Cutting-edge radiotherapies, such as stereotactic radiotherapy and particle 
therapy, have the potential to be a prospective option as a salvage modality.
The results of the PACIFIC clinical trial have led to the design of several clinical 
trials combining radiotherapy with ICIs, including PACIFIC-2 study, where a chemo-
radiotherapy plus durvalumab arm is currently studied (NCT03519971). In addition, 
combining chemotherapy, radiotherapy, and ICIs with surgical resection is also 
under investigation in clinical trials (NCT03694236, NCT03237377, NCT04073745, 
NCT03348748).
There are oncological differences between pathological subtypes in NSCLC, as 
widely known in metastatic diseases [72]. Ito et al. showed that adenocarcinoma 
and squamous cell carcinoma tended to develop distant and locoregional fail-
ures, respectively, after chemoradiotherapy for locally advanced NSCLC [73]. In 
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ClinicalTrials.gov 
identifier
Study 
design
Brief of treatment
NCT04432142 Phase 2 Immune changes after concurrent chemoradiation followed by 
durvalumab
NCT03589547 Phase 2 Durvalumab and consolidation SBRT following chemoradiation
NCT04092283 Phase 3 Durvalumab as concurrent and consolidative therapy or 
consolidative therapy alone
NCT03801902 Phase 1 Accelerated or conventionally fractionated radiotherapy 
combined with durvalumab
NCT03663166 Phase 
1, 2
Chemoradiotherapy with ipilimumab followed by nivolumab
NCT04310020 Phase 2 Hypofractionated radiotherapy followed by atezolizumab
NCT03693300 Phase 2 Durvalumab following sequential chemotherapy and radiotherapy
NCT04249362 Phase 2 Durvalumab following radiotherapy (standard or 
hypofractionated bioequivalent dose)
NCT04392505 Phase 2 Investigating biomarkers related to chemoradiation followed by 
durvalumab
NCT04505267 Phase 1 Reirradiation with NBTXR3 for locoregional recurrence
Searched for: radiotherapy, immune | Recruiting, Not yet recruiting Studies | Non-small Cell Lung Cancer Stage III 
at https://clinicaltrials.gov with excluding trials including surgery on Sep. 7, 2020.
Table 2. 
Ongoing phase 1 to 3 clinical trials for locally advanced NSCLN in terms of definitive radiotherapy and 
immune therapy.
addition, non-squamous cell carcinoma tends to benefit more from adding dur-
valumab than squamous cell carcinoma, although there is a lack of direct compari-
son analysis [32]. The effects of histopathological and oncological differences in 
NSCLC on definitive chemoradiotherapy should be investigated with the aim of 
developing a precision treatment for locally advanced NSCLC.
5.2 Immune enhancement and preservation in radiotherapy
Recent developments in immunotherapy have started a new era in the treatment 
of various malignancies, including NSCLC [29, 30, 74]. Induction of the expression 
of immune checkpoint molecules such as PD-L1 results in the inhibition of T cell 
function and immune tolerance of tumors.
Radiation may cause immune activation through cytokine signaling and tumor 
antigen release [75, 76]. However, PD-L1 expression in tumors has been reported 
to be upregulated by radiation exposure in both pre-clinical and clinical set-
tings and can suppress the immunogenic effect on tumors [75–78]. ICIs block the 
immunosuppressive mechanisms of cancer cells and have a synergistic effect in 
combination with radiotherapy [75, 77]. The addition of durvalumab was proven to 
benefit disease control and survival after definitive chemoradiotherapy for locally 
advanced NSCLC [28, 31, 32]. The density of CD8+ tumor-infiltrating lymphocytes 
was significantly associated with favorable survival in locally advanced NSCLC 
patients undergoing chemoradiotherapy [79]. In their report, PD-L1 expression, 
which could be blocked by ICIs, was associated with inferior survival. In addition, 
radiation-induced lymphopenia has been reported to be associated with inferior 
survival [80, 81]. Therefore, radiotherapy will be modified to enhance the immune 
response to tumors. Hypofractionated regimens might have less immunosuppres-
sive effects and are more appropriate than conventional fractionated regimens in 
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terms of immune preservation [82, 83]. A clinical trial has been designed to test 
the addition of durvalumab to two schedules of radiotherapies of conventional and 
hypofractionated schedules (NCT03801902). Ongoing clinical trials in terms of 
definitive radiotherapy combined with ICIs are summarized in Table 2.
PTV size can be associated with circulating blood, including the leukocytes [84]. 
Thus, IFRT is appropriate in terms of not only reducing the risk of pneumonitis 
but also preservation of the host immune system. Ladbury et al. have presented 
a predictive model of the estimated dose of radiation to immune cells, which was 
calculated using the radiation doses for heart, lung, body, and number of fractions, 
and was associated with cancer-specific outcomes [85]. Thereafter, sparing the host 
immune system will be discussed, and new optimizing theory for IMRT should be 
investigated in the future. Radio-immune therapy strategy is giving a new direc-
tion to radiotherapy and is warranted to explore future definitive radiotherapy for 
locally advanced NSCLC.
6. Conclusions
In this chapter, the historical improvement and the current recommendation 
of definitive radiotherapy for locally advanced NSCLC are described. The current 
standard treatment for locally advanced NSCLC is definitive radiotherapy, concur-
rently combined with chemotherapy, followed by anti-PD-L1 treatment. In order 
to improve outcomes and minimize radiation-induced toxicity, IMRT using an 
involved-field under modern management of respiration is a present recommenda-
tion in this chapter. An optimal combination of radiotherapy and immunotherapy 
should be warranted in a future investigation.
Acknowledgements
This work was supported by JSPS KAKENHI Grant Number JP20K08093.
Lung Cancer - Modern Multidisciplinary Management
10
Author details
Hiroshi Doi1* and Kozo Kuribayashi2
1 Department of Radiation Oncology, Kindai University Faculty of Medicine, 
Osaka-Sayama, Osaka, Japan
2 Division of Respiratory Medicine, Department of Internal Medicine, Hyogo 
College of Medicine, Nishinomiya, Hyogo, Japan
*Address all correspondence to: h-doi@med.kindai.ac.jp
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
11
Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status…
DOI: http://dx.doi.org/10.5772/intechopen.93927
References
[1] Walters S, Maringe C, Coleman MP, 
et al. Lung cancer survival and stage 
at diagnosis in Australia, Canada, 
Denmark, Norway, Sweden and the UK: 
a population-based study, 2004-2007. 
Thorax. 2013;68:551-564.
[2] NCCN Clinical Practice Guidelines in 
Oncology (NCCN Guidelines®) Non-
Small Cell Lung Cancer Version 6. 2020 
https://www.nccn.org/professionals/
physician_gls/pdf/nscl.pdf [Accessed: 
2020-Aug-01]
[3] Park K, Vansteenkiste J, Lee KH, 
Pentheroudakis G, Zhou C, Prabhash K, 
et al. Pan-Asian adapted ESMO Clinical 
Practice Guidelines for the management 
of patients with locally-advanced 
unresectable non-small-cell lung cancer: 
a KSMO-ESMO initiative endorsed by 
CSCO, ISMPO, JSMO, MOS, SSO and 
TOS. Ann Oncol. 2020;31:191-201.
[4] Roswit B, Patno ME, Rapp R, 
Veinbergs A, Feder B, Stuhlbarg J, et al. 
The Survival of Patients with Inoperable 
Lung Cancer: A Large-Scale 
Randomized Study of Radiation 
Therapy Versus Placebo. Radiology. 
1968;90:688-697.
[5] Perez CA, Pajak TF, Rubin P, 
Simpson JR, Mohiuddin M, Brady LW, 
et al. Long-term observations of the 
patterns of failure in patients with 
unresectable non-oat cell carcinoma 
of the lung treated with definitive 
radiotherapy. Report by the Radiation 
Therapy Oncology Group. Cancer. John 
Wiley & Sons, Ltd; 1987;59:1874-1881.
[6] Le Chevalier T, Arriagada R, Quoix E, 
Ruffle P, Martin M, Tarayre M, et al. 
Radiotherapy Alone Versus Combined 
Chemotherapy and Radiotherapy in 
Nonresectable Non-Small-Cell Lung 
Cancer: First Analysis of a Randomized 
Trial in 353 Patients. JNCI Journal 
of the National Cancer Institute. 
1991;83:417-423.
[7] Kubota K, Furuse K, Kawahara M, 
Kodama N, Yamamoto M, Ogawara M, 
et al. Role of radiotherapy in combined 
modality treatment of locally advanced 
non-small-cell lung cancer. Journal of 
Clinical Oncology. 1994;12:1547-1552.
[8] Dillman RO, Herndon J, Seagren SL, 
Eaton WL, Green MR. Improved 
Survival in Stage III Non-Small-Cell 
Lung Cancer: Seven-Year Follow-up 
of Cancer and Leukemia Group B 
(CALGB) 8433 Trial. JNCI Journal 
of the National Cancer Institute. 
1996;88:1210-1215.
[9] Sause W, Kolesar P, Taylor S IV, 
Johnson D, Livingston R, Komaki R, 
et al. Final results of phase III trial 
in regionally advanced unresectable 
non-small cell lung cancer: Radiation 
Therapy Oncology Group, Eastern 
Cooperative Oncology Group, and 
Southwest Oncology Group. Chest. 
2000;117:358-364.
[10] Furuse K, Fukuoka M, Kawahara M, 
Nishikawa H, Takada Y, Kudoh S, et al. 
Phase III Study of Concurrent Versus 
Sequential Thoracic Radiotherapy 
in Combination With Mitomycin, 
Vindesine, and Cisplatin in Unresectable 
Stage III Non–Small-Cell Lung 
Cancer. Journal of Clinical Oncology. 
1999;17:2692-2699.
[11] Fournel P, Robinet G, Thomas P, 
Souquet P-J, Lena H, Vergnenégre A, 
et al. Randomized phase III trial of 
sequential chemoradiotherapy compared 
with concurrent chemoradiotherapy in 
locally advanced non-small-cell lung 
cancer: Groupe Lyon-Saint-Etienne 
d'Oncologie Thoracique-Groupe 
Français de Pneumo-Cancérologie 
NPC 95-01 Study. Journal of Clinical 
Oncology. 2005;23:5910-5917.
[12] Auperin A, Le Pechoux C,  
Rolland E, Curran WJ, Furuse K,  
Fournel P, et al. Meta-Analysis of 
Lung Cancer - Modern Multidisciplinary Management
12
Concomitant Versus Sequential 
Radiochemotherapy in Locally 
Advanced Non–Small-Cell Lung 
Cancer. Journal of Clinical Oncology. 
2010;28:2181-2190.
[13] Curran WJ, Paulus R,  
Langer CJ, Komaki R, Lee JS, 
Hauser S, et al. Sequential vs Concurrent 
Chemoradiation for Stage III Non-Small 
Cell Lung Cancer: Randomized Phase 
III Trial RTOG 9410. JNCI Journal 
of the National Cancer Institute. 
2011;103:1452-1460.
[14] Schiller JH, Harrington D, 
Belani CP, et al: Comparison of four 
chemotherapy regimens for advanced 
non-small-cell lung cancer. N Engl J 
Med. 2002;346:92-98.
[15] Bunn PA Jr, Kelly K: New 
chemotherapeutic agents prolong 
survival and improve quality of life in 
non-small cell lung cancer: A review of 
the literature and future directions. Clin 
Cancer Res. 1998;4:1087-1100.
[16] Segawa Y, Kiura K, Takigawa N, 
Kamei H, Harita S, Hiraki S, et al. Phase 
III Trial Comparing Docetaxel and 
Cisplatin Combination Chemotherapy 
With Mitomycin, Vindesine, and 
Cisplatin Combination Chemotherapy 
With Concurrent Thoracic Radiotherapy 
in Locally Advanced Non–Small-Cell 
Lung Cancer: OLCSG 0007. Journal of 
Clinical Oncology. 2010;28:3299-3306.
[17] Yamamoto N, Nakagawa K, 
Nishimura Y, Tsujino K, Satouchi M, 
Kudo S, et al. Phase III Study Comparing 
Second- and Third-Generation 
Regimens With Concurrent Thoracic 
Radiotherapy in Patients With 
Unresectable Stage III Non–Small-Cell 
Lung Cancer: West Japan Thoracic 
Oncology Group WJTOG0105. Journal 
of Clinical Oncology. 2010;28:3739-3745.
[18] Saunders M, Dische S,  
Barrett A, Harvey A, Griffiths G,  
Palmar M. Continuous, 
hyperfractionated, accelerated 
radiotherapy (CHART) versus 
conventional radiotherapy in non-small 
cell lung cancer: mature data from the 
randomised multicentre trial. CHART 
Steering committee. Radiotherapy and 
Oncology. 1999;52:137-148.
[19] Nyman J, Friesland S, Hallqvist A, 
Seke M, Bergström S, Thaning L, et al. 
How to improve loco-regional control 
in stages IIIa-b NSCLC? Results of a 
three-armed randomized trial from 
the Swedish Lung Cancer Study Group. 
Lung Cancer. 2009;65:62-67.
[20] Haslett K, Pöttgen C, Stuschke M, 
Faivre-Finn C. Hyperfractionated 
and accelerated radiotherapy in non-
small cell lung cancer. J Thorac Dis. 
2014;6:328-335.
[21] Mauguen A, Le Pechoux C, 
Saunders MI, Schild SE, Turrisi AT, 
Baumann M, et al. Hyperfractionated 
or accelerated radiotherapy in 
lung cancer: an individual patient 
data meta-analysis. J Clin Oncol. 
2012;30:2788-2797.
[22] Baumann M, Herrmann T, Koch R, 
Matthiessen W, Appold S, Wahlers B, 
et al. Final results of the randomized 
phase III CHARTWEL-trial (ARO 
97-1) comparing hyperfractionated-
accelerated versus conventionally 
fractionated radiotherapy in non-small 
cell lung cancer (NSCLC). Radiotherapy 
and Oncology. 2011;100:76-85.
[23] Hanna N, Neubauer M,  
Yiannoutsos C, McGarry R, 
Arseneau J, Ansari R, et al. Phase III 
Study of Cisplatin, Etoposide, and 
Concurrent Chest Radiation With or 
Without Consolidation Docetaxel 
in Patients With Inoperable Stage III 
Non–Small-Cell Lung Cancer: The 
Hoosier Oncology Group and U.S. 
Oncology. Journal of Clinical Oncology. 
2008;26:5755-5760.
[24] Ahn JS, Ahn YC, Kim J-H, Lee CG, 
Cho EK, Lee KC, et al. Multinational 
13
Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status…
DOI: http://dx.doi.org/10.5772/intechopen.93927
Randomized Phase III Trial With or 
Without Consolidation Chemotherapy 
Using Docetaxel and Cisplatin 
After Concurrent Chemoradiation 
in Inoperable Stage III Non–Small-
Cell Lung Cancer: KCSG-LU05-04. 
Journal of Clinical Oncology. 
2015;33:2660-2666.
[25] Tsujino K, Kurata T,  
Yamamoto S, Kawaguchi T, Kubo A,  
Isa S, et al. Is consolidation 
chemotherapy after concurrent chemo-
radiotherapy beneficial for patients 
with locally advanced non-small-
cell lung cancer? A pooled analysis 
of the literature. J Thorac Oncol. 
2013;8:1181-1189.
[26] Martel M. Estimation of tumor 
control probability model parameters 
from 3-D dose distributions of non-
small cell lung cancer patients. Lung 
Cancer. 1999;24:31-37.
[27] Bradley JD, Paulus R, Komaki R, 
Masters G, Blumenschein G, Schild S, 
et al. Standard-dose versus high-dose 
conformal radiotherapy with concurrent 
and consolidation carboplatin plus 
paclitaxel with or without cetuximab for 
patients with stage IIIA or IIIB non-
small-cell lung cancer (RTOG 0617): a 
randomised, two-by-two factorial phase 
3 study. Lancet Oncol. 2015;16:187-199.
[28] Gray JE, Villegas A, Daniel D,  
Vicente D, Murakami S, Hui R, et al.  
Three-Year Overall Survival with 
Durvalumab after Chemoradiotherapy 
in Stage III NSCLC-Update 
from PACIFIC. J Thorac Oncol. 
2020;15:288-293.
[29] Granier C, De Guillebon E, Blanc C, 
Roussel H, Badoual C, Colin E, et al. 
Mechanisms of action and rationale 
for the use of checkpoint inhibitors in 
cancer. ESMO Open. 2017;2:e000213.
[30] Wagner G, Stollenwerk HK,  
Klerings I. Efficacy and safety of 
immune checkpoint inhibitors in 
patients with advanced non–small cell 
lung cancer (NSCLC): a systematic 
literature review. OncoImmunology. 
2020;9:1.
[31] Antonia SJ, Villegas A, Daniel D, 
Vicente D, Murakami S, Hui R, et al. 
Durvalumab after Chemoradiotherapy 
in Stage III Non–Small-Cell 
Lung Cancer. N Engl J Med. 
2017;377:1919-1929.
[32] Antonia SJ, Villegas A, Daniel D, 
Vicente D, Murakami S, Hui R, et al. 
Overall Survival with Durvalumab after 
Chemoradiotherapy in Stage III NSCLC. 
N Engl J Med. 2018;379:2342-2350.
[33] Bradley JD, Hu C, Komaki RR, 
Masters GA, Blumenschein GR, 
Schild SE, et al. Long-Term Results of 
NRG Oncology RTOG 0617: Standard- 
Versus High-Dose Chemoradiotherapy 
With or Without Cetuximab for 
Unresectable Stage III Non-Small-
Cell Lung Cancer. J Clin Oncol. 
2020;38:706-714.
[34] Yom SS, Liao Z, Liu HH, Tucker SL, 
Hu C-S, Wei X, et al. Initial Evaluation 
of Treatment-Related Pneumonitis 
in Advanced-Stage Non–Small-Cell 
Lung Cancer Patients Treated With 
Concurrent Chemotherapy and 
Intensity-Modulated Radiotherapy. 
International Journal of Radiation 
Oncology*Biology*Physics. 
2007;68:94-102.
[35] HU Y, LI J, SU X. Fatal pneumonitis 
associated with postoperative intensity-
modulated radiotherapy in lung cancer: 
Case report and review. Oncol Lett. 
2012;5:714-716.
[36] Tsujino K, Hashimoto T, 
Shimada T, Yoden E, Fujii O, Ota Y, et 
al. Combined Analysis of V20, VS5, 
Pulmonary Fibrosis Score on Baseline 
Computed Tomography, and Patient 
Age Improves Prediction of Severe 
Radiation Pneumonitis After 
Concurrent Chemoradiotherapy for 
Locally Advanced Non–Small-Cell Lung 
Lung Cancer - Modern Multidisciplinary Management
14
Cancer. Journal of Thoracic Oncology. 
2014;9:983-990.
[37] Chun SG, Hu C, Choy H, 
Komaki RU, Timmerman RD, Schild SE, 
et al. Impact of Intensity-Modulated 
Radiation Therapy Technique for 
Locally Advanced Non-Small-Cell 
Lung Cancer: A Secondary Analysis 
of the NRG Oncology RTOG 0617 
Randomized Clinical Trial. J Clin Oncol. 
2017;35:56-62.
[38] Palma DA, Senan S, Tsujino K, 
Barriger RB, Rengan R, Moreno M,  
et al. Predicting Radiation Pneumonitis 
After Chemoradiation Therapy 
for Lung Cancer: An International 
Individual Patient Data Meta-
analysis. International Journal of 
Radiation Oncology*Biology*Physics. 
2013;85:444-450.
[39] Speirs CK, DeWees TA, Rehman S, 
Molotievschi A, Velez MA, Mullen D, 
et al. Heart Dose Is an Independent 
Dosimetric Predictor of Overall 
Survival in Locally Advanced Non-
Small Cell Lung Cancer. J Thorac Oncol. 
2017;12:293-301.
[40] Movsas B, Hu C, Sloan J, Bradley J, 
Komaki R, Masters G, et al. Quality 
of Life Analysis of a Radiation Dose-
Escalation Study of Patients With 
Non-Small-Cell Lung Cancer: A 
Secondary Analysis of the Radiation 
Therapy Oncology Group 0617 
Randomized Clinical Trial. JAMA 
Oncol. 2016;2:359-367.
[41] Eaton BR, Pugh SL, Bradley JD, 
Masters G, Kavadi VS, Narayan S, et al. 
Institutional Enrollment and Survival 
Among NSCLC Patients Receiving 
Chemoradiation: NRG Oncology 
Radiation Therapy Oncology Group 
(RTOG) 0617. J Natl Cancer Inst. 
2016;108: djw034.
[42] Tan MY, Fisher R, Ball D. Does 
institutional patient accrual volume 
impact overall survival in patients with 
inoperable non-small-cell lung cancer 
receiving radical (chemo)radiation? 
A secondary analysis of TROG 99.05. 
Journal of Medical Imaging and 
Radiation Oncology. 2020;64:556-562.
[43] Wuthrick EJ, Zhang Q, MacHtay M, 
Rosenthal DI, Nguyen-Tan PF, Fortin A, 
et al. Institutional clinical trial accrual 
volume and survival of patients with 
head and neck cancer. J Clin Oncol. 
2015;33:156-164.
[44] Harada H, Murayama S. Proton 
beam therapy in non-small cell lung 
cancer: state of the art. Lung Cancer 
(Auckl). 2017;8:141-145.
[45] Liao Z, Lee JJ, Komaki R, 
Gomez DR, O'Reilly MS, Fossella FV, et 
al. Bayesian Adaptive Randomization 
Trial of Passive Scattering Proton 
Therapy and Intensity-Modulated 
Photon Radiotherapy for Locally 
Advanced Non-Small-Cell Lung Cancer. 
J Clin Oncol. 2018;36:1813-1822.
[46] Nestle U, De Ruysscher D, Ricardi U, 
Geets X, Belderbos J, Pöttgen C, et al. 
ESTRO ACROP guidelines for target 
volume definition in the treatment of 
locally advanced non-small cell lung 
cancer. Radiotherapy and Oncology. 
2018;127:1-5.
[47] Grills IS, Yan D, Martinez AA,  
Vicini FA, Wong JW, Kestin LL. 
Potential for reduced toxicity and 
dose escalation in the treatment of 
inoperable non–small-cell lung cancer: 
A comparison of intensity-modulated 
radiation therapy (IMRT), 3D 
conformal radiation, and elective nodal 
irradiation. International Journal of 
Radiation Oncology*Biology*Physics. 
2003;57:875-890.
[48] Schild SE, McGinnis WL, 
Graham D, Hillman S, Fitch TR, 
Northfelt D, et al. Results of a Phase 
I trial of concurrent chemotherapy 
and escalating doses of radiation for 
unresectable non–small-cell lung 
15
Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status…
DOI: http://dx.doi.org/10.5772/intechopen.93927
cancer. International Journal of 
Radiation Oncology*Biology*Physics. 
2006;65:1106-1111.
[49] Bradley JD, Bae K, Graham MV,  
Byhardt R, Govindan R, Fowler J,  
et al. Primary analysis of the phase 
II component of a phase I/II dose 
intensification study using three-
dimensional conformal radiation 
therapy and concurrent chemotherapy 
for patients with inoperable non-small-
cell lung cancer: RTOG 0117. J Clin 
Oncol. 2010;28:2475-2480.
[50] Rosenzweig KE, Sim SE,  
Mychalczak B, Braban LE, 
Schindelheim R, Leibel SA. Elective 
nodal irradiation in the treatment 
of non-small-cell lung cancer with 
three-dimensional conformal radiation 
therapy. Int J Radiation Oncology Biol 
Phys. 2001;50:681-685.
[51] Rosenzweig KE, Sura S,  
Jackson A, Yorke E. Involved-field 
radiation therapy for inoperable non 
small-cell lung cancer. J Clin Oncol. 
2007;25:5557-5561.
[52] Sulman EP, Komaki R, Klopp AH, 
Cox JD, Chang JY. Exclusion of elective 
nodal irradiation is associated with 
minimal elective nodal failure in non-
small cell lung cancer. Radiat Oncol. 
2009;4:5.
[53] De Ruysscher D, Wanders S, van 
Haren E, Hochstenbag M, Geeraedts W, 
Utama I, et al. Selective mediastinal 
node irradiation based on FDG-PET 
scan data in patients with non-small-cell 
lung cancer: a prospective clinical study. 
Int J Radiation Oncology Biol Phys. 
2005;62:988-994.
[54] Yuan S, Sun X, Li M, Yu J, Ren R, 
Yu Y, et al. A Randomized Study of 
Involved-Field Irradiation Versus 
Elective Nodal Irradiation in 
Combination With Concurrent 
Chemotherapy for Inoperable Stage 
III Nonsmall Cell Lung Cancer. 
American Journal of Clinical Oncology. 
2007;30:239-244.
[55] Chen M, Bao Y, Ma H-L, Hu X, 
Wang J, Wang Y, et al. Involved-Field 
Radiotherapy versus Elective Nodal 
Irradiation in Combination with 
Concurrent Chemotherapy for Locally 
Advanced Non-Small Cell Lung 
Cancer: A Prospective Randomized 
Study. BioMed Research International. 
2013;2013:1-7.
[56] Fernandes AT, Shen J, Finlay J, 
Mitra N, Evans T, Stevenson J, et al. 
Elective nodal irradiation (ENI) vs. 
involved field radiotherapy (IFRT) 
for locally advanced non-small cell 
lung cancer (NSCLC): A comparative 
analysis of toxicities and clinical 
outcomes. Radiotherapy and Oncology. 
2010;95:178-184.
[57] Nestle U, Schimek-Jasch T, Kremp S, 
Schaefer-Schuler A, Mix M, Küsters A, 
et al. Imaging-based target volume 
reduction in chemoradiotherapy for 
locally advanced non-small-cell lung 
cancer (PET-Plan): a multicentre, open-
label, randomised, controlled trial. 
Lancet Oncol. 2020;21:581-592.
[58] Giraud P, Antoine M, Larrouy A, 
Milleron B, Callard P, De Rycke Y, et 
al. Evaluation of microscopic tumor 
extension in non-small-cell lung cancer 
for three-dimensional conformal 
radiotherapy planning. Int J Radiation 
Oncology Biol Phys. 2000;48:1015-1024.
[59] Yuan S, Meng X, Yu J, Mu D, 
Chao KSC, Zhang J, et al. Determining 
optimal clinical target volume 
margins on the basis of microscopic 
extracapsular extension of metastatic 
nodes in patients with non–small-cell 
lung cancer. International Journal of 
Radiation Oncology, Biology, Physics. 
2007;67:727-734.
[60] Seppenwoolde Y, Shirato H, 
Kitamura K, Shimizu S, van Herk M, 
Lebesque JV, et al. Precise and real-time 
Lung Cancer - Modern Multidisciplinary Management
16
measurement of 3D tumor motion in 
lung due to breathing and heartbeat, 
measured during radiotherapy. Int 
J Radiation Oncology Biol Phys. 
2002;53:822-834.
[61] Giraud P, Morvan E, Claude L, 
Mornex F, Le Pechoux C, Bachaud 
J-M, et al. Respiratory gating 
techniques for optimization of lung 
cancer radiotherapy. J Thorac Oncol. 
2011;6:2058-2068.
[62] Boda-Heggemann J, Knopf 
A-C, Simeonova-Chergou A, 
Wertz H, Stieler F, Jahnke A, et al. Deep 
Inspiration Breath Hold-Based Radiation 
Therapy: A Clinical Review. Int J Radiat 
Oncol Biol Phys. 2016;94:478-492.
[63] Mirjana Josipovic, et al. Deep 
inspiration breath hold in locally 
advanced lung cancer radiotherapy: 
validation of intrafractional geometric 
uncertainties in the INHALE trial. Br J 
Radiol. 2019;92:20190569.
[64] Kilburn JM, Soike MH, Lucas JT, 
Ayala-Peacock D, Blackstock W, Isom S, 
et al. Image guided radiation therapy 
may result in improved local control 
in locally advanced lung cancer 
patients. Practical Radiation Oncology. 
2016;6:e73–e80.
[65] Giacometti V, King RB, Agnew CE, 
Irvine DM, Jain S, Hounsell AR, et 
al. An evaluation of techniques 
for dose calculation on cone beam 
computed tomography. Br J Radiol. 
2019;92:20180383.
[66] Tvilum M, Khalil AA, Møller DS, 
Hoffmann L, Knap MM. Clinical 
outcome of image-guided adaptive 
radiotherapy in the treatment of 
lung cancer patients. Acta Oncol. 
2015;54:1430-1437.
[67] Lozano Ruiz FJ, Ileana Pérez 
Álvarez S, Poitevin Chacón MA, 
Maldonado Magos F, Prudencio RR, 
Cabrera Miranda L, et al.  
The importance of image guided 
radiotherapy in small cell lung cancer: 
Case report and review of literature. 
Reports of Practical Oncology and 
Radiotherapy. 2020;25:146-149.
[68] Raben D, Rimner A, Senan S, et al. 
Patterns of disease progression with 
durvalumab in stage III non-small cell 
lung cancer (PACIFIC). Int J Radiation 
Oncology Biol Phys. 105:683.
[69] Taugner J, Eze C,  
KÄSMANN L, Roengvoraphoj O, 
Gennen K, Karin M, et al. Pattern-of-
failure and salvage treatment analysis 
after chemoradiotherapy for inoperable 
stage III non-small cell lung cancer. 
Radiation Oncology; 2020;15:148.
[70] Schreiner W, Dudek W, 
Lettmaier S, Fietkau R, Sirbu H. Long-
Term Survival after Salvage Surgery 
for Local Failure after Definitive 
Chemoradiation Therapy for Locally 
Advanced Non-small Cell Lung 
Cancer. Thorac cardiovasc Surg. 
2018;66:135-141.
[71] Palma DA, Olson R, Harrow S, 
Gaede S, Louie AV, Haasbeek C, et al. 
Stereotactic ablative radiotherapy versus 
standard of care palliative treatment in 
patients with oligometastatic cancers 
(SABR-COMET): a randomised, 
phase 2, open-label trial. Lancet. 
2019;393:2051-2058.
[72] Socinski MA, Obasaju C, Gandara D, 
Hirsch FR, Bonomi P, Bunn P, et al. 
Clinicopathologic Features of Advanced 
Squamous NSCLC. J Thorac Oncol. 
2016;11:1411-1422.
[73] Ito H, Matsuo Y, Ohtsu S, 
Nishimura T, Terada Y, Sakamoto T, 
et al. Impact of histology on patterns 
of failure and clinical outcomes 
in patients treated with definitive 
chemoradiotherapy for locally advanced 
non-small cell lung cancer. Int J Clin 
Oncol.2019;25:274-281.
17
Definitive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer: Current Status…
DOI: http://dx.doi.org/10.5772/intechopen.93927
[74] Sanmamed MF, Chen L. A Paradigm 
Shift in Cancer Immunotherapy: From 
Enhancement to Normalization. Cell. 
2018;175:313-326.
[75] Grassberger C, Ellsworth SG, 
Wilks MQ, Keane FK, Loeffler JS. 
Assessing the interactions between 
radiotherapy and antitumour immunity. 
Nat Rev Clin Oncol. 2019;16:729-745.
[76] Le Q-T, Shirato H,  
Giaccia AJ, Koong AC. Emerging 
Treatment Paradigms in Radiation 
Oncology. Clin Cancer Res. 
2015;21:3393-3401.
[77] Deng L, Liang H, Burnette B, 
Beckett M, Darga T, Weichselbaum RR, 
et al. Irradiation and anti–PD-L1 
treatment synergistically promote 
antitumor immunity in mice. J Clin 
Invest. 2014;124:687-695.
[78] Yoneda K, Kuwata T, 
Kanayama M, Mori M, Kawanami T, 
Yatera K, et al. Alteration in tumoural 
PD-L1 expression and stromal 
CD8-positive tumour-infiltrating 
lymphocytes after concurrent chemo-
radiotherapy for non-small cell lung 
cancer. Br J Cancer. 2019;121:490-496.
[79] Tokito T, Azuma K, Kawahara A, 
Ishii H, Yamada K, Matsuo N, et al. 
Predictive relevance of PD-L1 expression 
combined with CD8+ TIL density 
in stage III non-small cell lung 
cancer patients receiving concurrent 
chemoradiotherapy. Eur J Cancer. 
2016;55:7-14.
[80] Tang C, Liao Z, Gomez D, Levy L, 
Zhuang Y, Gebremichael RA, et al. 
Lymphopenia association with gross 
tumor volume and lung V5 and its 
effects on non-small cell lung cancer 
patient outcomes. Int J Radiat Oncol Biol 
Phys. 2014;89:1084-1091.
[81] Wang W, Huang L, Jin J-Y, Jolly S, 
Zang Y, Wu H, et al. IDO Immune Status 
after Chemoradiation May Predict 
Survival in Lung Cancer Patients. 
Cancer Research. 2018;78:809-816.
[82] Wang W, Huang L, Jin J-Y, 
Pi W, Ellsworth SG, Jolly S, et al. A 
Validation Study on IDO Immune 
Biomarkers for Survival Prediction 
in Non-Small Cell Lung Cancer: 
Radiation Dose Fractionation Effect in 
Early-Stage Disease. Clin Cancer Res. 
2020;26:282-289.
[83] Crocenzi T, Cottam B, Newell P, 
Wolf RF, Hansen PD, Hammill C, et al. 
A hypofractionated radiation regimen 
avoids the lymphopenia associated with 
neoadjuvant chemoradiation therapy 
of borderline resectable and locally 
advanced pancreatic adenocarcinoma. 
Journal for ImmunoTherapy of Cancer. 
2016;4:45.
[84] Yovino S, Kleinberg L, Grossman SA, 
Narayanan M, Ford E. The etiology 
of treatment-related lymphopenia 
in patients with malignant gliomas: 
modeling radiation dose to circulating 
lymphocytes explains clinical 
observations and suggests methods 
of modifying the impact of radiation 
on immune cells. Cancer Invest. 
2013;31:140-144.
[85] Ladbury CJ, Rusthoven CG, 
Camidge DR, Kavanagh BD, Nath SK. 
Impact of Radiation Dose to the Host 
Immune System on Tumor Control and 
Survival for Stage III Non-Small Cell 
Lung Cancer Treate d with Definitive 
Radiation Therapy. International Journal 
of Radiation Oncology*Biology*Physics. 
2019;105:346-355.
